ArticleCancer immunology, immunotherapy : CII2021
Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Sarah B Reusing et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.